新型司美格鲁肽在 2 型糖尿病和肥胖症中的应用：临床证据与展望。
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
机构信息
Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, 410008, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, 410008, China.
出版信息
Front Med. 2022 Feb;16(1):17-24. doi: 10.1007/s11684-021-0873-2. Epub 2022 Feb 28.
Abstract
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
摘要
肥胖是 2 型糖尿病（T2D）的一个重要危险因素，已成为威胁人类健康的重要因素。然而，目前还没有针对肥胖的完美药物选择。司美格鲁肽是一种人胰高血糖素样肽-1（GLP-1）类似物，通过葡萄糖浓度依赖的机制促进胰岛素分泌，同时抑制胰高血糖素分泌。GLP-1 还可以延缓胃排空并抑制食欲，从而帮助减肥。本综述总结了司美格鲁肽治疗 T2D 和肥胖的临床证据，并对未来肥胖治疗的临床试验建立了预期。
相似文献
1
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.新型司美格鲁肽在 2 型糖尿病和肥胖症中的应用：临床证据与展望。
Front Med. 2022 Feb;16(1):17-24. doi: 10.1007/s11684-021-0873-2. Epub 2022 Feb 28.
2
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.皮下注射和口服司美格鲁肽制剂的临床应用观点。
Front Endocrinol (Lausanne). 2021 Jun 29;12:645507. doi: 10.3389/fendo.2021.645507. eCollection 2021.
3
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
4
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.新型 GLP-1 受体激动剂司美格鲁肽在减轻肥胖、非酒精性脂肪性肝炎和神经退行性疾病中的治疗潜力：叙事性综述。
Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1.
5
Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.司美格鲁肽在2型糖尿病管理中的概况：设计、研发及治疗地位
Drug Des Devel Ther. 2019 Feb 20;13:731-738. doi: 10.2147/DDDT.S165372. eCollection 2019.
6
[New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus tablets), an oral GLP-1 receptor agonist].2型糖尿病新药：口服司美格鲁肽（Rybelsus片）介绍，一种口服胰高血糖素样肽-1（GLP-1）受体激动剂
Nihon Yakurigaku Zasshi. 2022;157(2):146-154. doi: 10.1254/fpj.21052.
7
[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].[司美格鲁肽，每周一次的胰高血糖素样肽-1受体激动剂（奥泽米皮克®）]
Rev Med Liege. 2019 Sep;74(9):488-494.
8
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.口服司美格鲁肽治疗 2 型糖尿病患者的疗效和安全性临床评价：考虑接受注射用 GLP-1 受体激动剂治疗或正在接受胰岛素治疗的患者。
Postgrad Med. 2020 Nov;132(sup2):26-36. doi: 10.1080/00325481.2020.1798127. Epub 2020 Sep 8.
9
Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.口服司美格鲁肽治疗2型糖尿病：临床现状与比较分析
Curr Drug Targets. 2022;23(3):311-327. doi: 10.2174/1389450122666210901125420.
10
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?将口服司美格鲁肽纳入初级保健的临床实践：为谁、何时以及如何使用？
Postgrad Med. 2020 Nov;132(sup2):48-60. doi: 10.1080/00325481.2020.1798162. Epub 2020 Sep 8.
引用本文的文献
1
Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.司美格鲁肽和腺苷可减轻肥胖诱导的肾损伤，并观察到对Txnip/NLRP3通路的调节作用。
Diabetol Metab Syndr. 2025 May 24;17(1):164. doi: 10.1186/s13098-025-01736-2.
2
Metabolic pathways mediating insulin resistance and gestational diabetes mellitus discovered by high-dimensional systematic Mendelian randomization.通过高维系统孟德尔随机化发现的介导胰岛素抵抗和妊娠期糖尿病的代谢途径。
Cardiovasc Diabetol. 2025 May 9;24(1):195. doi: 10.1186/s12933-025-02746-0.
3
Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system.美国食品药品监督管理局不良事件报告系统中与胰高血糖素样肽-1受体激动剂相关的骨折事件。
Acta Diabetol. 2024 Nov 18. doi: 10.1007/s00592-024-02415-w.
4
Alternate-day fasting delays pubertal development in normal-weight mice but prevents high-fat diet-induced obesity and precocious puberty.隔日禁食会延迟正常体重小鼠的青春期发育，但可预防高脂肪饮食诱导的肥胖和性早熟。
Nutr Diabetes. 2024 Oct 4;14(1):82. doi: 10.1038/s41387-024-00335-w.
5
The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.司美格鲁肽对 2 型糖尿病患者血压的影响：系统评价和荟萃分析。
Endocrine. 2024 Mar;83(3):571-584. doi: 10.1007/s12020-023-03636-9. Epub 2023 Dec 15.
本文引用的文献
1
Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.改变 2 型糖尿病治疗方法：在整个治疗过程中比较胰高血糖素样肽-1 受体激动剂和磺脲类药物。
Diabetes Metab Res Rev. 2021 Oct;37(7):e3434. doi: 10.1002/dmrr.3434. Epub 2021 Feb 7.
2
Cardiovascular Imaging in Obesity.肥胖症的心血管影像学
Nutrients. 2021 Feb 26;13(3):744. doi: 10.3390/nu13030744.
3
COVID-19 and metabolic diseases: a heightened awareness of health inequities and a renewed focus for research priorities.新型冠状病毒肺炎和代谢性疾病：提高对健康不平等现象的认识，重新关注研究重点。
Cell Metab. 2021 Mar 2;33(3):473-478. doi: 10.1016/j.cmet.2021.02.006. Epub 2021 Feb 8.
4
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
5
Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the General Population - Analysis of a Nationwide Epidemiological Database.一般人群中代谢健康型肥胖与心血管疾病风险——基于全国性流行病学数据库的分析
Circ J. 2021 May 25;85(6):914-920. doi: 10.1253/circj.CJ-20-1040. Epub 2021 Feb 5.
6
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.糖尿病、肥胖症、新陈代谢与新型冠状病毒感染：开端的结束。
Cell Metab. 2021 Mar 2;33(3):479-498. doi: 10.1016/j.cmet.2021.01.016. Epub 2021 Jan 21.
7
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.利拉鲁肽 3.0mg 每日治疗精神分裂症、分裂情感性障碍和首发精神病患者超重和肥胖的疗效：一项先导性随机、双盲、安慰剂对照试验的结果。
Diabetes Obes Metab. 2021 Jun;23(6):1262-1271. doi: 10.1111/dom.14334. Epub 2021 Feb 16.
8
Hypoxia and hypoxia-inducible factors in diabetes and its complications.糖尿病及其并发症中的缺氧和缺氧诱导因子。
Diabetologia. 2021 Apr;64(4):709-716. doi: 10.1007/s00125-021-05380-z. Epub 2021 Jan 26.
9
Cardiorespiratory fitness in patients with type 2 diabetes: A missing piece of the puzzle.2 型糖尿病患者的心肺适能：缺失的一环。
Heart Fail Rev. 2021 Mar;26(2):301-308. doi: 10.1007/s10741-020-10015-3.
10
The risk of cardiovascular complications with current obesity drugs.当前肥胖症药物的心血管并发症风险。
Expert Opin Drug Saf. 2020 Sep;19(9):1095-1104. doi: 10.1080/14740338.2020.1806234. Epub 2020 Sep 9.
Zotero 插件